

=> file registry
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 08:54:15 ON 27 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 MAR 2007 HIGHEST RN 928196-39-8
DICTIONARY FILE UPDATES: 26 MAR 2007 HIGHEST RN 928196-39-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10524048ring5.str



chain nodes :
 6 7 8 9 12 13 14 15 16 17 23 24 25 26 27 28 29 30
 ring nodes :
 1 2 3 4 5
 chain bonds :
 1-27 1-24 2-28 2-6 4-8 4-25 5-23 5-26 6-7 6-29 6-30 8-9 12-13 14-15
 15-16 15-17
 ring bonds :
 1-5 1-2 2-3 3-4 4-5
 exact/norm bonds :
 1-5 1-24 1-2 2-3 3-4 4-5 4-8 5-23 6-7 8-9 12-13 14-15 15-16 15-17
 exact bonds :
 1-27 2-28 2-6 4-25 5-26 6-29 6-30

G1:O,S,S02

G2:OH, [*1], [*2]

G3:O,S,NH

G4:C,S,P

Match level :



1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 12:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 23:CLASS 24:CLASS 25:CLASS
26:CLASS 27:CLASS
28:CLASS 29:CLASS 30:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O, S, SO2

G2 OH, [O1], [O2]

G3 O, S, NH

G4 C, S, P

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 08:54:40 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2426 TO ITERATE

82.4% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.02

50 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 45566 TO 51474

PROJECTED ANSWERS: 2593 TO 4151

L2 50 SEA SSS SAM L1

=> d l2 scan


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN α -D-Arabinofuranoside, methyl O-2,3,5-tris-O-(phenylmethyl)- β -D-arabinofuranosyl-(1 \rightarrow 2)-O-3,5-bis-O-(phenylmethyl)- α -D-arabinofuranosyl-(1 \rightarrow 3)-O-[3,5-bis-O-(phenylmethyl)- α -D-


arabinofuranosyl-(1→5)]-2-O-(phenylmethyl)-(9CI)
MF C77 H84 O17

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 2-A




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN β -D-Glucopyranoside, 1-methylhexyl 6-O- β -D-xylofuranosyl- (9CI)
MF C18 H34 O10


Absolute stereochemistry. Rotation (-).
Currently available stereo shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN D-Ribofuranoside-3,4,5,5-C-d4, methyl, tris(4-methylbenzoate) (9CI)
 MF C30 H26 D4 O8

Absolute stereochemistry.



L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Nonanoic acid, 9-[[2-O-benzoyl-5-O-[(S)-[5-O-[(1,1-dimethylethyl)diphenylsilyl]-1-S-ethyl-3-O-(phenylmethyl)-1-thio- α -D-arabinofuranos-2-O-yl](4-methoxyphenyl)methyl]-3-O-(phenylmethyl)- α -D-arabinofuranosyl]oxy]-, methyl ester (9CI)
 MF C67 H82 O13 S Si


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN D-Xylofuranose, 3-O-butyl-, triacetate (9CI)
 MF C15 H24 O8

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>

Uploading C:\Program Files\Stnexp\Queries\10524048dummy.str



chain nodes :
 5 6 7
 chain bonds :
 5-6 6-7
 exact/norm bonds :
 5-6

exact bonds :
6-7

G1:O,S,SO2

G2:OH

G3:O,S,NH

G4:C,S,P

Match level :
5:CLASS 6:CLASS 7:CLASS

L3 STRUCTURE UPLOADED

=> s l3 sub=L2

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):sam
SAMPLE SUBSET SEARCH INITIATED 08:57:22 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED - 50 TO ITERATE

100.0% PROCESSED 50 ITERATIONS
SEARCH TIME: 00.00.01

7 ANSWERS


PROJECTIONS (WITHIN SPECIFIED SUBSET):	ONLINE	**COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):	576 TO	1424
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):	7 TO	298

L4 7 SEA SUB=L2 SSS SAM L3

=> d l4 scan

L4 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN D-Arabinose, O-5-O-acetyl-2,3-di-O-benzoyl- α -D-arabinofuranosyl-
(1 \rightarrow 5)-O-[2,3,5-tri-O-benzoyl- α -D-arabinofuranosyl-
(1 \rightarrow 3)]- (9CI)
MF C52 H48 O19

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3


L4 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN L-Arabinose, O-5-O-[(2E)-3-(4-hydroxy-3-methoxyphenyl)-1-oxo-2-propenyl]-
α-L-arabinofuranosyl-(1→5)-O-2-O-[(2E)-3-(4-hydroxy-3-
methoxyphenyl)-1-oxo-2-propenyl]-α-L-arabinofuranosyl-(1→5)-
(9CI)


MF C35 H42 O19

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT




L4 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Prymnesin 2, N-[(2S)-methoxy-2-naphthalenylacetyl]- (9CI)

MF C109 H146 Cl3 N O37

Absolute stereochemistry.
Double bond geometry as shown.






PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN β -D-Galactofuranoside, 9-decenyl 5-O- α -D-arabinofuranosyl-

(9CI)
MF C21 H38 O10

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>

Uploading C:\Program Files\Stnexp\Queries\10524048dummy2.str

chain nodes :
5 6 7
chain bonds :
5-6 6-7
exact/norm bonds :
5-6
exact bonds :
6-7

G1:O,S,SO2

G2:OH

G3:O,S,NH

G4:C,S,P

Match level :
5:CLASS 6:CLASS 7:CLASS

L5 STRUCTURE UPLOADED

=> s 15 sub=L2

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):sam
SAMPLE SUBSET SEARCH INITIATED 08:58:34 FILE 'REGISTRY'

SAMPLE SUBSET SCREEN SEARCH COMPLETED -

10 TO ITERATE

100.0% PROCESSED 10 ITERATIONS
SEARCH TIME: 00.00.01

4 ANSWERS

PROJECTIONS (WITHIN SPECIFIED SUBSET): ONLINE **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET): 11 TO 389
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET): 4 TO 200


L6 4 SEA SUB=L2 SSS SAM L5

=> d l6 scan


L6 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Uridine, 5'-C-[3-[3-[2-(2-amino-1,4,5,6-tetrahydro-4-pyrimidinyl)-N-[[[(1-carboxy-2-methylpropyl)amino]carbonyl]glycyl-3-hydroxyleucyl]amino]propyl]-1-dodecyl-2,5-dioxo-4-imidazolidinyl]-5'-O-[5-deoxy-5-[[[(dodecylamino)carbonyl]amino]-2-O-methyl-β-D-ribofuranosyl]-, (5'R)- (9CI)
MF C64 H111 N13 O18

Absolute stereochemistry.
Currently available stereo shown.

PAGE 1-A



PAGE 1-B




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L6 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN D-Ribofuranoside, 2-aminoethyl, 2,3,5-tribenzoate (9CI)
MF C28 H27 N O8
CI COM

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Prymnesin 2, N-acetyl-85-dechloro-85,86-didehydro- (9CI)
MF C98 H137 Cl2 N O36
CI COM


Absolute stereochemistry.

Double bond geometry as described by E or Z.


PAGE 1-C




PAGE 2-A



PAGE 2-B



PAGE 2-C




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Prymnesin 2, N-[(2S)-methoxy-2-naphthalenylacetyl]- (9CI)
MF C109 H146 Cl3 N O37




Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-C



PAGE 1-D





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> log hold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

3.60

3.81

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 08:59:07 ON 27 MAR 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'REGISTRY' AT 09:09:10 ON 27 MAR 2007

FILE 'REGISTRY' ENTERED AT 09:09:10 ON 27 MAR 2007

COPYRIGHT (C) 2007 American Chemical Society (ACS)

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION



FULL ESTIMATED COST

3.60

3.81

=>

Uploading C:\Program Files\Stnexp\Queries\10524048OH2.str



chain nodes :
 6 7 8 13 14 15 16 17 18 19
 ring nodes :
 1 2 3 4 5
 chain bonds :
 1-15 2-16 2-6 4-7 4-13 5-14 5-19 6-18 6-17 7-8
 ring bonds :
 1-5 1-2 2-3 3-4 4-5
 exact/norm bonds :
 1-5 1-2 2-3 3-4 4-5 4-7 5-19 7-8
 exact bonds :
 1-15 2-16 2-6 4-13 5-14 6-18 6-17

G1:O,S,SO2

G2:OH

G3:O,S,NH

G4:C,S,P



Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 13:CLASS
14:CLASS
15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS

L7 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10524-48OH3.str



chain nodes :

6 7 8 13 14 15 16 17 18 19

ring nodes :

1 2 3 4 5

chain bonds :

1-15 1-19 2-16 2-6 4-7 4-13 5-14 6-18 6-17 7-8

ring bonds :
1-5 1-2 2-3 3-4 4-5
exact/norm bonds :
1-5 1-2 1-19 2-3 3-4 4-5 4-7 7-8
exact bonds :
1-15 2-16 2-6 4-13 5-14 6-18 6-17

G1:O,S,SO2

G2:OH

G3:O,S,NH


G4:C,S,P

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 13:CLASS
14:CLASS
15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS

L8 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10524048OH5.str



```

chain nodes :
6  7  8 13 14 15 16 17 18 19
ring nodes :
1  2  3  4  5
chain bonds :
1-15 2-16 2-6  4-7  4-13 5-14 6-18 6-17 6-19 7-8
ring bonds :
1-5 1-2 2-3 3-4 4-5
exact/norm bonds :
1-5 1-2 2-3 3-4 4-5 4-7 6-19 7-8
exact bonds :
1-15 2-16 2-6 4-13 5-14 6-18 6-17

```

G1:O,S,SO2

G2:OH

G3:O,S,NH

G4:C,S,P

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 13:CLASS
14:CLASS
15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS

L9 STRUCTURE UPLOADED

=> d l3 scan
L3 HAS NO ANSWERS

=> d his

(FILE 'HOME' ENTERED AT 08:54:03 ON 27 MAR 2007)

FILE 'REGISTRY' ENTERED AT 08:54:15 ON 27 MAR 2007

L1 STRUCTURE UPLOADED
L2 50 S L1
L3 STRUCTURE UPLOADED
L4 7 S L3 SUB=L2 SAM
L5 STRUCTURE UPLOADED
L6 4 S L5 SUB=L2 SAM
L7 STRUCTURE UPLOADED
L8 STRUCTURE UPLOADED
L9 STRUCTURE UPLOADED

=> s (L7 or L8 or L9) sub=L2
ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):sam
SAMPLE SUBSET SEARCH INITIATED 09:11:05 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED - 50 TO ITERATE

100.0% PROCESSED 50 ITERATIONS 27 ANSWERS
SEARCH TIME: 00.00.01


PROJECTIONS (WITHIN SPECIFIED SUBSET):	ONLINE	**COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):	576 TO	1424
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):	229 TO	851

L10 27 SEA SUB=L2 SSS SAM (L7 OR L8 OR L9)

=> d l10 scan

L10 27 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN β -D-Glucopyranoside, 1-methylhexyl 6-O- β -D-xylofuranosyl- (9CI)
MF C18 H34 O10

Absolute stereochemistry. Rotation (-).
Currently available stereo shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L10 27 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN D-Ribofuranose, 1,2,3-tris(2-methylpropanoate) (9CI)
 MF C17 H28 O8


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 27 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN α -D-Lyxofuranoside, octyl 2,3-anhydro-5-O- α -D-arabinofuranosyl-
 (9CI)
 MF C18 H32 O8


Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 27 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN α -D-Arabinofuranoside, methyl O- α -D-arabinofuranosyl-
 (1 \rightarrow 3)-O-[α -D-arabinofuranosyl-(1 \rightarrow 5)]- (9CI)
 MF C16 H28 O13

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>

Uploading C:\Program Files\Stnexp\Queries\10524048N5.str



chain nodes :
 6 7 8 13 14 15 16 17 18 19
 ring nodes :
 1 2 3 4 5
 chain bonds :
 1-15 2-16 2-6 4-7 4-13 5-14 6-18 6-17 6-19 7-8
 ring bonds :
 1-5 1-2 2-3 3-4 4-5
 exact/norm bonds :
 1-5 1-2 2-3 3-4 4-5 4-7 6-19 7-8
 exact bonds :
 1-15 2-16 2-6 4-13 5-14 6-18 6-17

G1:O,S,SO2

G2:OH

G3:O,S,NH

G4:C,S,P



Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 13:CLASS
14:CLASS
15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS

L11 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10524048N3.str



chain nodes :

6 7 8 13 14 15 16 17 18 19

ring nodes :

1 2 3 4 5

chain bonds :

1-15 1-19 2-16 2-6 4-7 4-13 5-14 6-18 6-17 7-8

ring bonds :

1-5 1-2 2-3 3-4 4-5

exact/norm bonds :
1-5 1-2 1-19 2-3 3-4 4-5 4-7 7-8
exact bonds :
1-15 2-16 2-6 4-13 5-14 6-18 6-17

G1:O,S,SO2

G2:OH

G3:O,S,NH



G4:C,S,P

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 13:CLASS
14:CLASS
15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS

L12 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10524048N2.str



```

chain nodes :
6 7 8 13 14 15 16 17 18 19
ring nodes :
1 2 3 4 5
chain bonds :
1-15 2-16 2-6 4-7 4-13 5-14 5-19 6-18 6-17 7-8
ring bonds :
1-5 1-2 2-3 3-4 4-5
exact/norm bonds :
1-5 1-2 2-3 3-4 4-5 4-7 5-19 7-8
exact bonds :
1-15 2-16 2-6 4-13 5-14 6-18 6-17

```

G1:O,S,S02

G2:OH

G3:O,S,NH

G4:C,S,P

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 13:CLASS
14:CLASS
15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS

L13 STRUCTURE UPLOADED

=> s (L11 or L12 or L13) sub=L2

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):sam

SAMPLE SUBSET SEARCH INITIATED 09:12:20 FILE 'REGISTRY'

SAMPLE SUBSET SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED

1 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):

ONLINE **COMPLETE**

PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):

1 TO 80

PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):

1 TO 80

L14 1 SEA SUB=L2 SSS SAM (L11 OR L12 OR L13)

=> d l14 scan

L14 1 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN


IN Uridine, 5'-C-[3-[3-[2-(2-amino-1,4,5,6-tetrahydro-4-pyrimidinyl)-N-[[[(1-carboxy-2-methylpropyl)amino]carbonyl]glycyl-3-hydroxyleucyl]amino]propyl]-1-dodecyl-2,5-dioxo-4-imidazolidinyl]-5'-O-[5-deoxy-5-[[[(dodecylamino)carbonyl]amino]-2-O-methyl-β-D-ribofuranosyl]-, (5'R)-(9CI)


MF C64 H111 N13 O18

Absolute stereochemistry.

Currently available stereo shown.

PAGE 1-A





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss full

FULL SEARCH INITIATED 09:12:48 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 49789 TO ITERATE

100.0% PROCESSED 49789 ITERATIONS

3350 ANSWERS

SEARCH TIME: 00.00.01

L15 3350 SEA SSS FUL L1

=> s (L11 or L12 or L13) sub=L15

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full

FULL SUBSET SEARCH INITIATED 09:13:02 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 136 TO ITERATE

100.0% PROCESSED 136 ITERATIONS

124 ANSWERS

SEARCH TIME: 00.00.01

L16 124 SEA SUB=L15 SSS FUL (L11 OR L12 OR L13)

=> s (L7 or L8 or L9) sub=L16

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full

FULL SUBSET SEARCH INITIATED 09:13:16 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 122 TO ITERATE

100.0% PROCESSED 122 ITERATIONS

109 ANSWERS

SEARCH TIME: 00.00.01


L17 109 SEA SUB=L16 SSS FUL (L7 OR L8 OR L9)

=> d l17 scan

L17 109 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[methyl[3-[(phenylmethyl)amino]propyl]amino]-(9CI)

MF C32 H47 N5 O13




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3



L17 109 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Uridine, 5'-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-5'-C-[(2S)-2,3,4,7-tetrahydro-1,4-dimethyl-5-[(octadecyloxy)carbonyl]-3-oxo-1H-1,4-diazepin-2-yl]-, (5'S)- (9CI)
 MF C45 H75 N5 O14

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L17 109 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[[3-[[[4-(1-ethylbutoxy)phenyl]acetyl]amino]propyl]methylamino]- (9CI)
 MF C39 H59 N5 O15



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L17 109 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Uridine, 5'-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-5'-C-[(2S)-5-[(heptadecylamino)carbonyl]-2,3,4,7-tetrahydro-1,4-dimethyl-3-oxo-1H-1,4-diazepin-2-yl]-, (5'S) - (9CI)
 MF C44 H74 N6 O13

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

259.70

259.91

FILE 'CAPLUS' ENTERED AT 09:13:39 ON 27 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Mar 2007 VOL 146 ISS 14

FILE LAST UPDATED: 26 Mar 2007 (20070326/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l17

L18 16 L17

=> d l18 1-16 ti abs bib

L18 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of caprazene and caprazol and derivatives thereof as antibacterial agents

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Caprazene (I; R = OH; A = H) and caprazol (II; R7 = OH, R8 = H, A = H) are prepared by hydrolysis of caprazamycins. Caprazene-1'''-amide derivs. of the general formula I (R = NHR1; R1 = linear or branched C5-21 alkyl or alkenyl, C5-12 cycloalkyl, Ph substituted by linear C1-14 alkyl, linear C1-9 alkoxy, or C5-12 cycloalkyl at p-position; A = H, alkoxycarbonyl, Boc, aralkyloxycarbonyl, benzyloxycarbonyl) and caprazene-1'''-ester derivs. of the general formula I (R = OR2; R2 = linear or branched C5-21 alkyl, alkenyl, or alkynyl; A = same as above) or pharmaceutically acceptable acid addition salts thereof are prepared from caprazene. Caprazol-1'''-amide derivative of the general formula II (R7 = NHR3; R8 = H; R3 = R1 = linear or branched C5-21 alkyl or alkenyl, C5-12 cycloalkyl), caprazol-1'''-amide -3'''-ester derivs. II (R7 = NHR3; R8 = COR4; A = H; R3 = same as above; R4 = linear or branched C5-21 alkyl, alkenyl, or alkynyl), and caprazol-3'''-ester derivs. or pharmaceutically acceptable acid addition salts thereof are prepared from caprazol. Further, imidazolidinone derivs. (III; R6 = linear or branched C1-21 alkyl) are prepared from a product obtained from caprazol via ring opening of the 1,4-diazepinone ring. The novel caprazene derivs., the novel caprazol derivs., and the novel imidazolidinone derivs. exhibit excellent antibacterial activities against various bacteria including acid-fast bacteria.

AN 2004:648537 CAPLUS <<LOGINID::20070327>>

DN 141:190997

TI Preparation of caprazene and caprazol and derivatives thereof as antibacterial agents

IN Miake, Toshiaki; Igarashi, Masayuki; Shidara, Tetsuo; Takahashi, Yoshiaki; Hamada, Masa

PA Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai, Japan; Meiji Seika Kaisha, Ltd.

SO PCT Int. Appl., 112 pp.

CODEN: PIXXD2

DT Patent

LA Japanese


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004067544	A1	20040812	WO 2004-JP969	20040130
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
	CA 2514930	A1	20040812	CA 2004-2514930	20040130
	EP 1593684	A1	20051109	EP 2004-706817	20040130
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2006178319	A1	20060810	US 2005-543887	20050729
PRAI	JP 2003-25323	A	20030131		
	WO 2004-JP969	W	20040130		
OS	MARPAT 141:190997				

L18 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

TI Arabinofuranose disaccharide analogs as inhibitors of Mycobacterium tuberculosis

GI



AB Several octyl 5-O-(α -D-arabinofuranosyl)- α -D-arabinofuranoside disaccharide analogs substituted at the 5-position of the non-reducing end sugar were synthesized and tested in vitro against Mycobacterium tuberculosis (M.tb.), Mycobacterium avium complex (MAC) as well as in a cell free assay system for arabinosyltransferase acceptor/inhibitor activity. A few compds., [e.g., (I)], showed interesting inhibitory activity in the cell free assay as well as against the whole microorganism in vitro.

AN 2003:929130 CAPLUS <<LOGINID::20070327>>

DN 140:146366

TI Arabinofuranose disaccharide analogs as inhibitors of Mycobacterium tuberculosis

AU Pathak, Ashish K.; Pathak, Vibha; Kulshrestha, Manish; Kinnaird, Darren; Suling, William J.; Gurcha, S. S.; Besra, Gurdyal S.; Reynolds, Robert C.

CS Drug Discovery Division, Southern Research Institute, Birmingham, AL, 35255, USA

SO Tetrahedron (2003), 59(51), 10239-10248

CODEN: TETRAB; ISSN: 0040-4020

PB Elsevier Science B.V.

DT Journal

LA English


OS CASREACT 140:146366

RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of novel nucleoside peptide antibiotics AA-896

GI



AB The invention relates to antibiotic compds. AA-896 of formula I [R1 = H, aryl, (C1-C20)-alkyl, aryl-CH2, alkyl-CO, alkyl-NHCO, or aryl-NHCO; R2 = H, alkyl, aryl-CH2, or alkyl-CO; R3 = OH (R1 = R2 ≠ H when R3 = OH) or R2R3 = CONR4, where R4 = alkyl or aryl] or their pharmaceutically acceptable salts. Thus, treatment of I (R1 = R2 = H, R3 = OH) with methanol with pyridine and 2,4-pentanedione overnight at room temperature and then 4-fluorophenyl isocyanate in DMF afforded I (R1 = H, R4 = 4-fluorophenyl), which was assayed for antibacterial activity against a spectrum of Gram-pos. and Gram-neg. bacteria (MIC ≥ 32 µf/mL).

AN 2002:832769 CAPLUS <<LOGINID::20070327>>

DN 137:338138

TI Preparation of novel nucleoside peptide antibiotics AA-896

IN Lin, Yang-I.; Li, Zhong; Francisco, Gerardo Delacruz; McDonald, Leonard Alexander

PA American Cyanamid Company, USA

SO PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002085867	A1	20021031	WO 2002-US13024	20020425
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2003054983	A1	20030320	US 2002-131939	20020425
	US 6727232	B2	20040427		
	US 2003087874	A1	20030508	US 2002-131938	20020425
	US 6858591	B2	20050222		
	US 2003104986	A1	20030605	US 2002-132005	20020425
	US 6689763	B2	20040210		
	US 2004116334	A1	20040617	US 2003-713881	20031114
	US 7078195	B2	20060718		
PRAI	US 2001-286297P	P	20010425		
	US 2001-290140P	P	20010510		
	US 2001-286401P	P	20010425		
	US 2001-286402P	P	20010425		
	US 2001-290139P	P	20010510		
	US 2001-290156P	P	20010510		

US 2002-132005 A3 20020425
OS MARPAT 137:338138
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
TI Muraymycins, novel peptidoglycan biosynthesis inhibitors: semisynthesis and SAR of Their derivatives
AB Sixteen muraymycin derivs. were synthesized based on selective reactions of the primary and secondary amino groups of muraymycin C1 with isocyanates and aldehydes. Disubstituted derivs. demonstrated no activity against either MraY or MurG at ≤ 100 $\mu\text{g/mL}$ whereas mono substituted derivs. demonstrated good inhibitory activity, well correlated with the lipophilicity of the substituent introduced. In particular, the activity of derivs. substituted with Cl_2H_25 or CH_2Ph was comparable to that of muraymycin C1 in this assay.
AN 2002:585102 CAPLUS <<LOGINID::20070327>>
DN 138:39489
TI Muraymycins, novel peptidoglycan biosynthesis inhibitors: semisynthesis and SAR of Their derivatives
AU Lin, Yang-I.; Li, Zhong; Francisco, Gerardo D.; McDonald, Leonard A.; Davis, Rachel A.; Singh, Guy; Yang, Youjun; Mansour, Tarek S.
CS Chemical Sciences and Infectious Diseases, Wyeth Research, Pearl River, NY, 10965, USA
SO Bioorganic & Medicinal Chemistry Letters (2002), 12(17), 2341-2344
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 138:39489
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
TI Synthesis of analogues of the O- β -D-Ribofuranosyl Nucleoside Moiety of Liposidomycins. Part 1: contribution of the amino group and the Uracil Moiety upon the inhibition of MraY
GI



AB The O- β -D-ribofuranosyl nucleoside I is the minimal structural entity of liposidomycins maintaining enzyme inhibitory activity. Modifications performed on both the primary amine and the uracil moieties clearly demonstrate their major contribution to the inhibition of the bacterial translocase (MraY).
AN 2001:177408 CAPLUS <<LOGINID::20070327>>
DN 134:367120
TI Synthesis of analogues of the O- β -D-Ribofuranosyl Nucleoside Moiety of Liposidomycins. Part 1: contribution of the amino group and the Uracil

Moiety upon the inhibition of MraY

AU Dini, C.; Drochon, N.; Feteanu, S.; Guillot, J. C.; Peixoto, C.; Aszodi, J.

CS Medicinal Chemistry Department, Aventis Pharma, Romainville, 93235, Fr.

SO Bioorganic & Medicinal Chemistry Letters (2001), 11(4), 529-531

CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science Ltd.

DT Journal

LA English


OS CASREACT 134:367120

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L18 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

TI Syntheses of 6-guanidino-hexoses and 5-guanidino-pentoses


GI



I



II



III

AB Guanidination of primary amines were performed with 3,5-dimethylpyrazolylformamidine nitrate. 6-Deoxy-6-guanidino derivs. of unprotected N-acetyl-glucosamine and of glucosamine, e.g. I, were prepared, with both products existing as pyranoses. In the pentose series, e.g. 5-deoxy-5-guanidinio-D-xylose II and III were synthesized. For both compds., besides some α -D-xylo-pyranose and β -D-arabino-pyranose, mainly the furanoses are found.

AN 1994:299142 CAPLUS <<LOGINID::20070327>>

DN 120:299142

TI Syntheses of 6-guanidino-hexoses and 5-guanidino-pentoses

AU Wessel, Hans Peter

CS Pharma Div., F. Hoffmann-La Roche Ltd., Basel, CH 4002, Switz.

SO Journal of Carbohydrate Chemistry (1993), 12(8), 1173-86

CODEN: JCACDM; ISSN: 0732-8303

DT Journal


LA English

OS CASREACT 120:299142


L18 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of uronic acid (FR-900493) derivatives as antibacterial agents

GI



I



II

AB The title compds. [I; R1, R2 = (un)substituted NH2; R3 = (un)protected CO2H; R4 = H, OR9; R5 = H, OR10; R6 = OR11; R7 = H, R12; R9 - R12 = H, HO-protective group, or R9R10, R11R12 = (un)substituted lower alkylene; R8 = H, halo; X = N, N+R13; R13 = lower alkyl; Z = acid residue; n = 0,1; provided that when X = N+R13, R3 = protected CO2H and n = 1 or R3 = CO2H and n = 0] are prepared Thus, 0.52 g di-tert-Bu dicarbonate and 25 mL H2O were added to a solution of 1.04 g FR-900493 (II; X = X1 = H) in 15 mL 1,4-dioxane and then the mixture was stirred at room temperature for 10 h to give,

after column chromatog. using Diaion HP-20, II (R1 = H2N, R2 = Me3CO2CNH).

II [R1 = 4-[Me(CH2)7O]C6H4CH2CONH, R2 = H2N] showed min. inhibitory concentration

of 6.25 and 12.5 µg/mL against Staphylococcus aureus and Escherichia coli, resp. A total of 178 I including their salts were prepared

AN 1993:560727 CAPLUS <<LOGINID::20070327>>

DN 119:160727

TI Preparation of uronic acid (FR-900493) derivatives as antibacterial agents

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 57 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 05078385	A	19930330	JP 1991-196172	19910225
PRAI	GB 1990-4407	A	19900227		
OS	MARPAT 119:160727				

L18 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

TI Studies on immunoadjuvant active compounds. Part VI. Syntheses and immunoadjuvant activity of some carbohydrate analogs of N-acetylmuramyl-L-alanyl-D-isoglutamine

AB Carbohydrate analogs of N-acetylmuramyl-L-alanyl-D-isoglutamine, such as 2-acetamido-2,6-dideoxy-3-O- (D-2-propionyl-L-alanyl-D-isoglutamine)-L-glucopyranose, 2-acetamido-6-amino-2,6-dideoxy-3-O- (D-2-propionyl-L-alanyl-D-isoglutamine)-D-glucopyranose, and 2-acetamido-2-deoxy-3-O- (D-2-propionyl-L-alanyl-D-isoglutamine)-D-xylopyranose, were synthesized, and

their immunoadjuvant activities were examined to clarify their structural requirements for activity in the carbohydrate moiety.

AN 1980:584092 CAPLUS <<LOGINID::20070327>>

DN 93:184092

TI Studies on immunoadjuvant active compounds. Part VI. Syntheses and immunoadjuvant activity of some carbohydrate analogs of N-acetylmuramyl-L-alanyl-D-isoglutamine

AU Hasegawa, Akira; Okumura, Hiroyuki; Kiso, Makoto; Azuma, Ichiro; Yamamura, Yuichi

CS Dep. Agric. Chem., Gifu Univ., Gifu, 504, Japan

SO Agricultural and Biological Chemistry (1980), 44(6), 1301-8

CODEN: ABCHA6; ISSN: 0002-1369

DT Journal

LA English

L18 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

TI The behavior of some aldoses with 2,2-dialkoxypropane-N,N-dimethylformamide-p-toluenesulfonic acid. Part IX. Synthesis of 2,5-diacetamido-2,5-dideoxy- and 2,3,5-triacetamido-2,3,5-trideoxy-D-aldopentofuranose derivatives

AB 2,5-Diacetamido-1,3-di-O-acetyl-2,5-dideoxy- α -D-xylofuranose, 2,5-diacetamido-1,3-di-O-acetyl-2,5-dideoxy-D-ribofuranose, 2,3,5-triacetamido-1-O-acetyl-2,3,5-trideoxy- α -D-xylofuranose, and 2,3,5-triacetamido-1-O-acetyl-2,3,5-trideoxy- α (and β)-D-ribofuranose were synthesized from benzyl 2-(benzyloxycarbonylamino)-2-deoxy- β -xylofuranoside (I). The derived p-toluenesulfonate or methanesulfonate underwent displacement with azide ion, to yield, after reduction and acetylation, benzyl 2,5-diacetamido-3-O-acetyl-2,5-dideoxy- β -D-xylofuranoside, or benzyl 2,3,5-triacetamido-2,3,5-trideoxy- β -D-ribofuranoside (II), resp. Treatment with AcONa of benzyl 2-acetamido-5-azido-3-O-mesyl- β -D-xylofuranoside (III), prepared from I in four steps, gave benzyl 2-acetamido-5-azido-2,5-dideoxy- β -D-ribofuranoside (IV). Reduction of IV followed by acetylation, afforded the corresponding 2,5-diaminoribofuranoside derivative Benzyl 2,3,5-triacetamido-2,3,5-trideoxy- β -D-xylofuranoside (V) was synthesized by way of an azide-exchange reaction on benzyl 2-acetamido-5-azido-2,5-dideoxy-3-O-mesyl- β -D-ribofuranoside, derived from IV. Hydrogenation of benzyl 2,5-diacetamido-2,5-dideoxy- β -D-xylofuranoside and V, and benzyl 2,5-diacetamido-2,5-dideoxy- β -D-ribofuranoside and II followed by acetylation, gave the title compds. in good yields. Treatment of III or benzyl 2-acetamido-2-deoxy-3,5-di-O-mesyl- β -D-xylofuranoside, derived from benzyl 2-(benzyloxycarbonylamino)-2-deoxy-3,5-di-O-mesyl- β -D-xylofuranoside, with NaN₃ afforded 2-methyl-(benzyl 5-azido-2,3,5-trideoxy- β -D-ribofuranosido)-[2,3-d]-2-oxazoline in good yield. Evidence in support of the structures assigned to the new derivs. is presented.

AN 1980:495525 CAPLUS <<LOGINID::20070327>>

DN 93:95525

TI The behavior of some aldoses with 2,2-dialkoxypropane-N,N-dimethylformamide-p-toluenesulfonic acid. Part IX. Synthesis of 2,5-diacetamido-2,5-dideoxy- and 2,3,5-triacetamido-2,3,5-trideoxy-D-aldopentofuranose derivatives

AU Hasegawa, Akira; Aritake, Nobumitsu; Kiso, Makoto

CS Dep. Agric. Chem., Gifu Univ., Gifu, 504, Japan

SO Carbohydrate Research (1980), 81(1), 23-33

CODEN: CRBRAT; ISSN: 0008-6215


DT Journal

LA English


L18 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

TI Studies on hetero sugars. Part IV. Synthesis of a 2-acetamido-5-amino-2,5-dideoxy-D-xylopyranosyl derivative

GI




- AB 2-Acetamido-5-amino-2,5-dideoxy-D-xylopyranosyl hydrogen sulfite (I) was synthesized from benzyl 2-(benzyloxycarbonylamino)-2-deoxy-5,6-O-isopropylidene-β-D-glucofuranoside (II). O-Deisopropylidenation of II gave the triol which was converted, via oxidative cleavage at C-5-C-6 and subsequent reduction, into xylofuranoside III. Catalytic reduction of benzyl 2-(benzyloxycarbonylamino)-2-deoxy-5-O-tosyl-β-D-xylofuranoside, derived from III by selective tosylation, and subsequent N-acetylation, afforded benzyl 2-acetamido-2-deoxy-5-O-tosyl-β-D-xylofuranoside, which was treated with NaN₃ to give the corresponding 5-azido derivative IV. (Tetrahydropyran-2-yl)ation of the product formed by hydrolysis of IV gave 2-acetamido-5-azido-2,5-dideoxy-1,3-di-O-(tetrahydropyran-2-yl)-D-xylofuranose (V). Treatment of 2-acetamido-5-amino-2,5-dideoxy-1,3-O-(tetrahydropyran-2-yl)-D-xylofuranose, derived from V by reduction, with SO₂ in water gave I. Hydrogenation of IV and subsequent acetylation yielded 3-acetamido-4,5-diacetoxy-1-acetyl-xylo-piperidine.
- AN 1980:472157 CAPLUS <<LOGINID::20070327>>
 DN 93:72157
 TI Studies on hetero sugars. Part IV. Synthesis of a 2-acetamido-5-amino-2,5-dideoxy-D-xylopyranosyl derivative
 AU Hasegawa, Akira; Aritake, Nobumitsu; Kiso, Makoto
 CS Dep. Agric. Chem., Gifu Univ., Gifu, 504, Japan
 SO Carbohydrate Research (1980), 80(2), 277-83
 CODEN: CRBRAT; ISSN: 0008-6215
 DT Journal
 LA English
- L18 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Studies on heterosugars. Part II. Synthesis of 2,4-diamino-2,4-dideoxy-L-arabinose derivatives (prumycin derivatives)
 GI



- AB 2,4-Diamino-2,4-dideoxy-L-arabinose derivs. were prepared from benzyl 2-(benzyloxycarbonyl)amino-2-deoxy-β-D-glucofuranoside by a series of known reactions. Among the compds. prepared is furanoid prumycin I.
- AN 1978:152891 CAPLUS <<LOGINID::20070327>>
 DN 88:152891
 TI Studies on heterosugars. Part II. Synthesis of 2,4-diamino-2,4-dideoxy-L-arabinose derivatives (prumycin derivatives)
 AU Hsegawa, Akira; Sakurai, Tooru; Kiso, Makoto
 CS Dep. Agric. Chem., Gifu Univ., Gifu, Japan

SO Agricultural and Biological Chemistry (1978), 42(1), 153-8
 CODEN: ABCHA6; ISSN: 0002-1369
 DT Journal
 LA English


L18 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Synthesis of prumycin and related compounds
 GI



AB The title compds. I (R = D-alanyl, L-alanyl; R1 = H, D-alanyl).2HCl were prepared Thus, benzoylation of II followed by deisopropylidenation, oxidative cleavage, reduction, and hydrolysis gave III (R,R1 = H,OH; R2 = H; R3 = OH; R4 = Bz) (IV). Benzoylation of IV followed by mesylation and azidolysis gave III (R = PhCH2O, R1 = R3 = H, R2 = N3, R4 = Bz) (V). Debenzoylation of V followed by selective reduction and condensation with N-[N-(benzyloxycarbonyl)-D-alanyloxy]succinimide gave III [R = PhCH2O, R1 = R3 = H, R2 = D-PhCH2O2CNHCHMeCONH, R4 = H] (VI). Hydrogenolysis of VI gave prumycin (I, R = D-alanyl, R1 = H).2HCl.

AN 1977:155877 CAPLUS <<LOGINID::20070327>>
 DN 86:155877
 TI Synthesis of prumycin and related compounds
 AU Hasegawa, Akira; Aritake, Nobumitsu; Kiso, Makoto
 CS Dep. Agric. Chem., Gifu Univ., Gifu, Japan
 SO Carbohydrate Research (1976), 52(1), 137-49
 CODEN: CRBRAT; ISSN: 0008-6215
 DT Journal
 LA English

L18 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 TI A new synthesis of Prumycin
 GI



AB Benzoylation of I (X = CMe₂, R = H, Bn = PhCH₂, Cbz = PhCH₂O₂C) followed by deisopropylidenation gave I (X = H₂, R = Bz). Oxidative cleavage of I (X = H₂, R = Bz) followed by hydrolytic debenzoylation-rearrangement and subsequent benzylation gave II (R = Bz, R₁ = H, R₂ = OH) (III). Mesylation of III followed by azidolysis and saponification gave II (R = R₂ =

H,

R₁ = N₃), which underwent selective hydrogenation over Pd/C. The resultant II (R = R₂ = H, R₁ = NH₂) coupled with N-Cbz-D-Ala N-succinimide ester to give II [R = R₂ = H, R₁ = CbzNHCH(Me)CONH] (IV). Hydrogenation of IV with Pd/C in the presence of HOAc gave the title compound V.2HCl and its β-anomer.

AN 1977:16891 CAPLUS <<LOGINID::20070327>>

DN 86:16891

TI A new synthesis of Prumycin

AU Hasegawa, Akira; Aritake, Nobumitsu; Kiso, Makoto

CS Dep. Agric. Chem., Gifu Univ., Gifu, Japan

SO Carbohydrate Research (1976), 51(1), C10-C12

CODEN: CRBRAT; ISSN: 0008-6215

DT Journal

LA English

L18 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of aminomercapto furanose sugars from dithiocarbamoyl derivatives

AB Me 3-amino-3-deoxy-2-thio-α-D-ribofuranoside was prepared in several steps from Me 3-amino-3-deoxy-α-D-arabinofuranoside via Me 3-deoxy-3-(dithiocarbomethoxy)-amino-α-D-arabinofuranoside and 1'-O-methyl-α-D-ribofurano-[3',2':4,5]thiazolidine using the method of Goodman and Christensen (1963).

AN 1972:405759 CAPLUS <<LOGINID::20070327>>

DN 77:5759

TI Preparation of aminomercapto furanose sugars from dithiocarbamoyl derivatives

AU Goodman, Leon

CS Dep. Chem., Univ. Rhode Island, Kingston, RI, USA

SO Methods in Carbohydrate Chemistry (1972), 6, 277-81

CODEN: MCACAI; ISSN: 0097-3602

DT Journal

LA English

L18 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

TI Synthetic nucleosides. LXVIII. Studies on the synthesis of cis-2,3-diamino sugars. 8. Derivatives of 2,3-diamino-2,3-dideoxy-D-ribose and 2,3-dideoxy-2,3-imino-D-ribose

GI For diagram(s), see printed CA Issue.

AB cf. preceding abstract The N-methylsulfonyl derivative (I) of methyl 3-amino-3-deoxy-2,5-dio-O-methylsulfonyl-β-D-arabinofuranoside (II) undergoes cyclization in aqueous sodium hydroxide or with sodium acetate in hot HCONMe₂ to give methyl 2,3-dideoxy-2,3-dideoxy-2,3-imino-N-methylsulfonyl-5-O-methylsulfonyl-β-D-ribofuranoside (III). The cyclization of methyl 3-deoxy-2,5-di-O-methylsulfonyl-3-(3-phenylureido)-β-D-arabinofuranoside (IV) was also investigated.

AN 1966:36157 CAPLUS <<LOGINID::20070327>>

DN 64:36157

OREF 64:6734h,6735a-b

TI Synthetic nucleosides. LXVIII. Studies on the synthesis of cis-2,3-diamino sugars. 8. Derivatives of 2,3-diamino-2,3-dideoxy-D-ribose and 2,3-dideoxy-2,3-imino-D-ribose

AU Baker, B. R.; Hullar, T. L.

CS State Univ. of New York, Buffalo

SO Journal of Organic Chemistry (1965), 30(12), 4053-6

CODEN: JOCEAH; ISSN: 0022-3263

DT Journal

LA English
OS CASREACT 64:36157

L18 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
TI Use of a complex neighboring group to prepare amino(mercapto)furanose
sugars
GI For diagram(s), see printed CA Issue.
AB The conversion of Me 3-amino-3-deoxy- α -D-arabinofuranoside (I) to Me
3-amino-3-deoxy-2-thio- α -D-ribofuranoside hydrochloride (II) using a
dithiocarbamoyl neighboring group is described. The use of an alternative
procedure resulted in a C-3 to C-5 neighboring group participation and
ultimately yielded Me 3-amino-3-deoxy-2-O-(methylsulfonyl)-5-thio- α -
D-arabinofuranoside hydrochloride (III, X =SO₂Me).
AN 1963:469371 CAPLUS <<LOGINID::20070327>>
DN 59:69371
OREF 59:12891b-c
TI Use of a complex neighboring group to prepare amino(mercapto)furanose
sugars
AU Goodman, Leon; Christensen, James E.
CS Stanford Res. Inst., Menlo Park, CA
SO Journal of Organic Chemistry (1963), 28(10), 2610-13
CODEN: JOCEAH; ISSN: 0022-3263
DT Journal
LA Unavailable
OS CASREACT 59:69371

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	45.75	305.66
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-12.48	-12.48

FILE 'REGISTRY' ENTERED AT 09:14:31 ON 27 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 MAR 2007 HIGHEST RN 928196-39-8
DICTIONARY FILE UPDATES: 26 MAR 2007 HIGHEST RN 928196-39-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d his

(FILE 'HOME' ENTERED AT 08:54:03 ON 27 MAR 2007)

FILE 'REGISTRY' ENTERED AT 08:54:15 ON 27 MAR 2007

L1 STRUCTURE UPLOADED
L2 50 S L1
L3 STRUCTURE UPLOADED
L4 7 S L3 SUB=L2 SAM
L5 STRUCTURE UPLOADED
L6 4 S L5 SUB=L2 SAM
L7 STRUCTURE UPLOADED
L8 STRUCTURE UPLOADED
L9 STRUCTURE UPLOADED
L10 27 S (L7 OR L8 OR L9) SUB=L2 SAM
L11 STRUCTURE UPLOADED
L12 STRUCTURE UPLOADED
L13 STRUCTURE UPLOADED
L14 1 S (L11 OR L12 OR L13) SUB=L2 SAM
L15 3350 S L1 SSS FULL
L16 124 S (L11 OR L12 OR L13) SUB=L15 FULL
L17 109 S (L7 OR L8 OR L9) SUB=L16 FULL

FILE 'CAPLUS' ENTERED AT 09:13:39 ON 27 MAR 2007

L18 16 S L17

FILE 'REGISTRY' ENTERED AT 09:14:31 ON 27 MAR 2007

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.45	306.11
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-12.48

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 09:15:14 ON 27 MAR 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 09:21:01 ON 27 MAR 2007
FILE 'REGISTRY' ENTERED AT 09:21:01 ON 27 MAR 2007
COPYRIGHT (C) 2007 American Chemical Society (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.45	306.11
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-12.48

=> d his

(FILE 'HOME' ENTERED AT 08:54:03 ON 27 MAR 2007)

FILE 'REGISTRY' ENTERED AT 08:54:15 ON 27 MAR 2007

L1 STRUCTURE UPLOADED
L2 50 S L1
L3 STRUCTURE UPLOADED
L4 7 S L3 SUB=L2 SAM
L5 STRUCTURE UPLOADED
L6 4 S L5 SUB=L2 SAM
L7 STRUCTURE UPLOADED
L8 STRUCTURE UPLOADED
L9 STRUCTURE UPLOADED
L10 27 S (L7 OR L8 OR L9) SUB=L2 SAM
L11 STRUCTURE UPLOADED
L12 STRUCTURE UPLOADED
L13 STRUCTURE UPLOADED
L14 1 S (L11 OR L12 OR L13) SUB=L2 SAM
L15 3350 S L1 SSS FULL
L16 124 S (L11 OR L12 OR L13) SUB=L15 FULL
L17 109 S (L7 OR L8 OR L9) SUB=L16 FULL

FILE 'CAPLUS' ENTERED AT 09:13:39 ON 27 MAR 2007

L18 16 S L17

FILE 'REGISTRY' ENTERED AT 09:14:31 ON 27 MAR 2007

=> d l18 1-16 ti hitstr

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L18 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of caprazene and caprazol and derivatives thereof as antibacterial agents

IT 737759-78-3P 737759-79-4P 737759-80-7P
737759-81-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of caprazene and caprazol and derivs. thereof via hydrolysis of caprazamycins as antibacterial agents)

RN 737759-78-3 CAPLUS


CN Uridine, 5'-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-5'-C-[(2S)-5-[(dodecylamino)carbonyl]-2,3,4,7-tetrahydro-1,4-dimethyl-3-oxo-1H-1,4-diazepin-2-yl]-, (5'S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 737759-79-4 CAPLUS
 CN Uridine, 5'-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-5'-C-[(2S)-2,3,4,7-tetrahydro-1,4-dimethyl-3-oxo-5-[(tridecylamino)carbonyl]-1H-1,4-diazepin-2-yl]-, (5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 737759-80-7 CAPLUS
 CN Uridine, 5'-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-5'-C-[(2S)-2,3,4,7-tetrahydro-1,4-dimethyl-3-oxo-5-[(tetradecylamino)carbonyl]-1H-1,4-diazepin-2-yl]-, (5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 737759-81-8 CAPLUS
 CN Uridine, 5'-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-5'-C-[(2S)-2,3,4,7-tetrahydro-1,4-dimethyl-3-oxo-5-[(pentadecylamino)carbonyl]-1H-1,4-diazepin-2-yl]-, (5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 737760-32-6P 737760-33-7P 737760-34-8P
 737760-35-9P 737760-36-0P 737760-37-1P
 737760-38-2P 737760-39-3P 737760-40-6P
 737760-41-7P 737760-42-8P 737760-43-9P
 737760-44-0P 737760-45-1P 737760-46-2P
 737760-47-3P 737760-48-4P 737760-49-5P
 737760-50-8P 737760-51-9P 737760-52-0P
 737760-53-1P 737760-54-2P 737760-55-3P
 737760-64-4P 737760-65-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of caprazene and caprazol and derivs. thereof via hydrolysis of caprazamycins as antibacterial agents)

RN 737760-32-6 CAPLUS

CN Uridine, 5'-C-[(2S)-5-carboxy-2,3,4,7-tetrahydro-1,4-dimethyl-3-oxo-1H-1,4-diazepin-2-yl]-5'-O-[5-deoxy-5-[(1,1-dimethylethoxy)carbonylamino]-β-D-ribofuranosyl]-, (5'S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737760-33-7 CAPLUS

CN Uridine, 5'-O-[5-deoxy-5-[(1,1-dimethylethoxy)carbonylamino]-β-D-ribofuranosyl]-5'-C-[(2S)-5-[(hexylamino)carbonyl]-2,3,4,7-tetrahydro-1,4-dimethyl-3-oxo-1H-1,4-diazepin-2-yl]-, (5'S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



Chemical structure of compound 10, showing a complex molecule with a central bicyclic system, a methyl group, a t-butyl ester, and a pyridine ring.

RN	737760-35-9	CAPLUS
CN	Uridine, 5'-O-[5-deoxy-5-[[[(1,1-dimethylethoxy) carbonyl] amino]-β-D-ribofuranosyl]-5'-C-[(2S)-2,3,4,7-tetrahydro-1,4-dimethyl-5-[(octylamino) carbonyl]-3-oxo-1H-1,4-diazepin-2-yl]-, (5'S)- (9CI) (CA INDEX NAME)	


Absolute stereochemistry.



RN 737760-36-0 CAPLUS

CN Uridine, 5'-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]]-5'-C-[(2S)-2,3,4,7-tetrahydro-1,4-dimethyl-5-[(nonylamino)carbonyl]-3-oxo-1H-1,4-diazepin-2-yl]-, (5'S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737760-37-1 CAPLUS

CN Uridine, 5'-C-[(2S)-5-[(decylamino)carbonyl]-2,3,4,7-tetrahydro-1,4-dimethyl-3-oxo-1H-1,4-diazepin-2-yl]-5'-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]]-, (5'S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737760-38-2 CAPLUS

CN Uridine, 5'-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-5'-C-[(2S)-2,3,4,7-tetrahydro-1,4-dimethyl-3-oxo-5-[(undecylamino)carbonyl]-1H-1,4-diazepin-2-yl]-, (5'S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737760-39-3 CAPLUS

CN Uridine, 5'-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-5'-C-[(2S)-5-[(hexadecylamino)carbonyl]-2,3,4,7-tetrahydro-1,4-dimethyl-3-oxo-1H-1,4-diazepin-2-yl]-, (5'S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737760-40-6 CAPLUS

CN Uridine, 5'-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-5'-C-[(2S)-5-[(heptadecylamino)carbonyl]-2,3,4,7-tetrahydro-1,4-dimethyl-3-oxo-1H-1,4-diazepin-2-yl]-, (5'S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737760-41-7 CAPLUS

CN Uridine, 5'-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-5'-C-[(2S)-2,3,4,7-tetrahydro-1,4-dimethyl-5-[(octadecylamino)carbonyl]-3-oxo-1H-1,4-diazepin-2-yl]-, (5'S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737760-42-8 CAPLUS

CN Uridine, 5'-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-5'-C-[(2S)-2,3,4,7-tetrahydro-1,4-dimethyl-5-[(nonadecylamino)carbonyl]-3-oxo-1H-1,4-diazepin-2-yl]-, (5'S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737760-43-9 CAPLUS

CN Uridine, 5'-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-5'-C-[(2S)-5-[(eicosylamino)carbonyl]-2,3,4,7-tetrahydro-1,4-dimethyl-3-oxo-1H-1,4-diazepin-2-yl]-, (5'S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737760-44-0 CAPLUS

CN Uridine, 5'-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-5'-C-[(2S)-5-[(heneicosylamino)carbonyl]-2,3,4,7-tetrahydro-1,4-dimethyl-3-oxo-1H-1,4-diazepin-2-yl]-, (5'S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737760-45-1 CAPLUS

CN Uridine, 5'-C-[(2S)-5-[(cyclododecylamino)carbonyl]-2,3,4,7-tetrahydro-1,4-dimethyl-3-oxo-1H-1,4-diazepin-2-yl]-5'-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-, (5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 737760-46-2 CAPLUS

CN Uridine, 5'-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-5'-C-[(2S)-2,3,4,7-tetrahydro-1,4-dimethyl-5-[[[(9Z)-9-octadecenylamino]carbonyl]-3-oxo-1H-1,4-diazepin-2-yl]-, (5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

=O

RN 737760-47-3 CAPLUS

CN Uridine, 5'-C-[(2S)-5-[(decyloxy)carbonyl]-2,3,4,7-tetrahydro-1,4-dimethyl-3-oxo-1H-1,4-diazepin-2-yl]-5'-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-, (5'S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737760-48-4 CAPLUS

CN Uridine, 5'-O-[5-deoxy-5-[[[(1,1-dimethylethoxy) carbonyl] amino]-β-D-ribofuranosyl]-5'-C-[(2S)-2,3,4,7-tetrahydro-1,4-dimethyl-3-oxo-5-[(tridecyloxy) carbonyl]-1H-1,4-diazepin-2-yl]-, (5'S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737760-49-5 CAPLUS

CN Uridine, 5'-O-[5-deoxy-5-[[[(1,1-dimethylethoxy) carbonyl] amino]-β-D-ribofuranosyl]-5'-C-[(2S)-2,3,4,7-tetrahydro-1,4-dimethyl-5-[(octadecyloxy) carbonyl]-3-oxo-1H-1,4-diazepin-2-yl]-, (5'S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737760-50-8 CAPLUS

CN Uridine, 5'-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-5'-C-[(2S)-2,3,4,7-tetrahydro-1,4-dimethyl-3-oxo-5-[[[(11Z)-11-tetradecenyl]oxy]carbonyl]-1H-1,4-diazepin-2-yl]-, (5'S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 737760-51-9 CAPLUS

CN Uridine, 5'-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-5'-C-[(2S)-5-[[[(2E)-2-dodecenyl]oxy]carbonyl]-2,3,4,7-tetrahydro-1,4-dimethyl-3-oxo-1H-1,4-diazepin-2-yl]-, (5'S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 737760-52-0 CAPLUS

CN Uridine, 5'-O-[5-deoxy-5-[[1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-5'-C-[(2S)-2,3,4,7-tetrahydro-1,4-dimethyl-3-oxo-5-[(10-undecenyl)oxy)carbonyl]-1H-1,4-diazepin-2-yl]-, (5'S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737760-53-1 CAPLUS

CN Uridine, 5'-C-[(2S)-5-[(3-decynyl)oxy)carbonyl]-2,3,4,7-tetrahydro-1,4-dimethyl-3-oxo-1H-1,4-diazepin-2-yl]-5'-O-[5-deoxy-5-[[1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-, (5'S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




≡O

RN 737760-54-2 CAPLUS

CN Uridine, 5'-C-[(2S,5S,6S)-5-carboxyhexahydro-6-hydroxy-1,4-dimethyl-3-oxo-1H-1,4-diazepin-2-yl]-5'-O-[5-deoxy-5-[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl-, (5'S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737760-55-3 CAPLUS

CN Uridine, 5'-O-[5-deoxy-5-[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-5'-C-[(2S,5S,6S)-5-[(dodecylamino)carbonyl]hexahydro-6-hydroxy-1,4-dimethyl-3-oxo-1H-1,4-diazepin-2-yl]-, (5'S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737760-64-4 CAPLUS

CN D-glycero- α -L-talo-Heptofuranuronamide, 6-[[[(2S,3S)-3-carboxy-2-hydroxy-3-(methylamino)propyl]methylamino]-1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]- β -D-ribofuranosyl]-1-[3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 737760-65-5 CAPLUS


CN D-glycero- α -L-talo-Heptofuranuronamide, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]- β -D-ribofuranosyl]-1-[3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl]-6-[[[(2S)-2-[(4S)-1-dodecyl-3-methyl-2,5-dioxo-4-imidazolidinyl]-2-hydroxyethyl]methylamino]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L18 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Arabinofuranose disaccharide analogs as inhibitors of Mycobacterium tuberculosis
 IT 651706-73-9P 651706-74-0P
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of arabinofuranose disaccharide analogs and their activity as inhibitors of Mycobacterium tuberculosis)
 RN 651706-73-9 CAPLUS
 CN α -D-Arabinofuranoside, octyl 5-O-[5-deoxy-5-[(ethylsulfonyl)amino]- α -D-arabinofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651706-74-0 CAPLUS
 CN α -D-Arabinofuranoside, octyl 5-O-[5-deoxy-5-[[4-methylphenyl)sulfonyl]amino]- α -D-arabinofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of novel nucleoside peptide antibiotics AA-896

IT 474267-63-5P 474267-64-6P 474267-65-7P

474267-66-8P 474267-67-9P 474267-68-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel nucleoside peptide antibiotics AA-896)


RN 474267-63-5 CAPLUS

CN Uridine, 5'-C-[3-[3-[2-(2-amino-1,4,5,6-tetrahydro-4-pyrimidinyl)-N-[[[(1-carboxy-2-methylpropyl)amino]carbonyl]glycyl-3-hydroxyleucyl]amino]propyl]-1-octyl-2,5-dioxo-4-imidazolidinyl]-5'-O-[5-deoxy-2-O-methyl-5-[[[(octylamino)carbonyl]amino]-β-D-ribofuranosyl]-, (5'R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

Currently available stereo shown.

PAGE 1-A



PAGE 1-B




RN 474267-64-6 CAPLUS

CN Uridine, 5'-C-[3-[3-[2-(2-amino-1,4,5,6-tetrahydro-4-pyrimidinyl)-N-[[[(1-carboxy-2-methylpropyl)amino]carbonyl]glycyl-3-hydroxyleucyl]amino]propyl]-1-(4-fluorophenyl)-2,5-dioxo-4-imidazolidinyl]-5'-O-[5-deoxy-5-[[[(4-fluorophenyl)amino]carbonyl]amino]-2-O-methyl-β-D-ribofuranosyl]-, (5'R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Currently available stereo shown.

PAGE 1-A



PAGE 1-B

=O







RN 474267-65-7 CAPLUS

CN Uridine, 5'-C-[3-[3-[2-(2-amino-1,4,5,6-tetrahydro-4-pyrimidinyl)-N-[[[(1-carboxy-2-methylpropyl)amino]carbonyl]glycyl-3-hydroxyleucyl]amino]propyl]-1-(4-methoxyphenyl)-2,5-dioxo-4-imidazolidinyl]-5'-O-[5-deoxy-5-[[[(4-methoxyphenyl)amino]carbonyl]amino]-2-O-methyl-β-D-ribofuranosyl]-, (5'R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


Currently available stereo shown.






RN 474267-66-8 CAPLUS
 CN Uridine, 5'-C-[3-[3-[2-(2-amino-1,4,5,6-tetrahydro-4-pyrimidinyl)-N-[[[(1-carboxy-2-methylpropyl)amino]carbonyl]glycyl-3-hydroxyleucyl]amino]propyl]-1-hexyl-2,5-dioxo-4-imidazolidinyl]-5'-O-[5-deoxy-5-[[[(hexylamino)carbonyl]amino]-2-O-methyl-β-D-ribofuranosyl]-, (5'R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Currently available stereo shown.







RN 474267-67-9 CAPLUS

CN Uridine, 5'-C-[3-[3-[2-(2-amino-1,4,5,6-tetrahydro-4-pyrimidinyl)-N-[[[(1-carboxy-2-methylpropyl)amino]carbonyl]glycyl-3-hydroxyleucyl]amino]propyl]-1-dodecyl-2,5-dioxo-4-imidazolidinyl]-5'-O-[5-deoxy-5-[[[(dodecylamino)carbonyl]amino]-2-O-methyl-β-D-ribofuranosyl]-, (5'R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Currently available stereo shown.




RN 474267-68-0 CAPLUS

CN β-D-allo-Heptofuranuronic acid, 6-[[3-[2-(2-amino-1,4,5,6-tetrahydro-4-pyrimidinyl)-N-[[[(1-carboxy-2-methylpropyl)amino]carbonyl]glycyl-3-hydroxyleucyl]amino]propyl]amino]-1,6-dideoxy-5-O-[5-deoxy-5-[[[(hexadecylamino)carbonyl]amino]-2-O-methyl-β-D-ribofuranosyl]-1-


(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-, (6ξ)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Currently available stereo shown.

PAGE 1-A



PAGE 1-B




L18 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Muraymycins, novel peptidoglycan biosynthesis inhibitors: semisynthesis and SAR of Their derivatives
 IT 478409-90-4P
 RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation, MraY and MurG antimicrobial inhibitor evaluation of muraymycin derivs.)
 RN 478409-90-4 CAPLUS
 CN β-D-allo-Heptofuranuronic acid, 6-[[[3-[[2-(2-amino-1,4,5,6-tetrahydro-4-pyrimidinyl)-N-[[[(1S)-1-carboxy-2-methylpropyl]amino]carbonyl]glycyl-(3S)-3-hydroxy-L-leucyl]amino]propyl][(octylamino)carbonyl]amino]-1,6-


dideoxy-5-O- [5-deoxy-2-O-methyl-5- [[(octylamino) carbonyl] amino] - β -D-ribofuranosyl]-1- (3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-, (6 ξ)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Currently available stereo shown.

PAGE 1-A





PAGE 1-B



IT 474267-63-5P 474267-64-6P 474267-65-7P
474267-66-8P 474267-67-9P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);
BIOL (Biological study); PREP (Preparation)
(preparation, MraY and MurG antimicrobial inhibitor evaluation of muraymycin
derivs.)
RN 474267-63-5 CAPLUS
CN Uridine, 5'-C- [3- [3- [[2- (2-amino-1,4,5,6-tetrahydro-4-pyrimidinyl) -N- [[(1-
carboxy-2-methylpropyl) amino] carbonyl] glycy] -3-hydroxyleucyl] amino] propyl] -
1-octyl-2,5-dioxo-4-imidazolidinyl]-5'-O- [5-deoxy-2-O-methyl-5-
[[(octylamino) carbonyl] amino] - β -D-ribofuranosyl]-, (5'R) - (9CI) (CA
INDEX NAME)

Absolute stereochemistry.
Currently available stereo shown.





RN 474267-64-6 CAPLUS

CN Uridine, 5'-C-[3-[3-[2-(2-amino-1,4,5,6-tetrahydro-4-pyrimidinyl)-N-[(1-carboxy-2-methylpropyl)amino]carbonyl]glycyl-3-hydroxyleucyl]amino]propyl]-1-(4-fluorophenyl)-2,5-dioxo-4-imidazolidinyl]-5'-O-[5-deoxy-5-[[[(4-fluorophenyl)amino]carbonyl]amino]-2-O-methyl-β-D-ribofuranosyl]-, (5'R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Currently available stereo shown.




RN 474267-65-7 CAPLUS
 CN Uridine, 5'-C-[3-[3-[[2-(2-amino-1,4,5,6-tetrahydro-4-pyrimidinyl)-N-[[[(1-carboxy-2-methylpropyl)amino]carbonyl]glycyl-3-hydroxyleucyl]amino]propyl]-


1-(4-methoxyphenyl)-2,5-dioxo-4-imidazolidinyl]-5'-O-[5-deoxy-5-[[[(4-methoxyphenyl) amino] carbonyl] amino]-2-O-methyl-β-D-ribofuranosyl]-, (5'R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Currently available stereo shown.

PAGE 1-A





PAGE 1-B



NH₂



RN 474267-66-8 CAPLUS
 CN Uridine, 5'-C-[3-[3-[2-(2-amino-1,4,5,6-tetrahydro-4-pyrimidinyl)-N-[[[(1-carboxy-2-methylpropyl)amino]carbonyl]glycyl-3-hydroxyleucyl]amino]propyl]-1-hexyl-2,5-dioxo-4-imidazolidinyl]-5'-O-[5-deoxy-5-[[[(hexylamino)carbonyl]amino]-2-O-methyl-β-D-ribofuranosyl]-, (5'R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Currently available stereo shown.



RN 474267-67-9 CAPLUS
 CN Uridine, 5'-C-[3-[3-[2-(2-amino-1,4,5,6-tetrahydro-4-pyrimidinyl)-N-[[[(1-carboxy-2-methylpropyl)amino]carbonyl]glycyl-3-hydroxyleucyl]amino]propyl]-1-dodecyl-2,5-dioxo-4-imidazolidinyl]-5'-O-[5-deoxy-5-[[[(dodecylamino)carbonyl]amino]-2-O-methyl-β-D-ribofuranosyl]-, (5'R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Currently available stereo shown.



L18 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

TI Synthesis of analogues of the O- β -D-Ribofuranosyl Nucleoside Moiety
of Liposidomycins. Part 1: contribution of the amino group and the Uracil
Moiety upon the inhibition of MraY

IT 340739-03-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis of O-β-D-ribofuranosyl nucleoside analogs and structure activity inhibition of MraY)

RN 340739-03-9 CAPLUS


CN Uridine, 5'-O-[5-[(aminoiminomethyl)amino]-5-deoxy-β-D-ribofuranosyl]-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L18 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Syntheses of 6-guanidino-hexoses and 5-guanidino-pentoses
 IT 154919-52-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reaction of, in synthesis of 5-guanidino-pentoses)
 RN 154919-52-5 CAPLUS
 CN α -D-Arabinofuranoside, phenylmethyl 5-[(aminoiminomethyl)amino]-5-
 deoxy-, mononitrate (salt) (9CI) (CA INDEX NAME)
 CM 1
 CRN 154919-51-4
 CMF C13 H19 N3 O4

Absolute stereochemistry.



CM 2
 CRN 7697-37-2
 CMF H N O3



L18 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Preparation of uronic acid (FR-900493) derivatives as antibacterial agents
 IT 149385-94-4P 149385-96-6P 149386-00-5P
 149386-06-1P 149386-07-2P 149386-14-1P
 149386-25-4P 149386-28-7P 149386-29-8P
 149386-37-8P 149386-38-9P 149386-40-3P
 149386-46-9P 149386-50-5P 149386-57-2P
 149386-60-7P 149386-66-3P 149386-69-6P
 149386-72-1P 149386-76-5P 149386-79-8P
 149386-81-2P 149386-83-4P 149386-85-6P
 149386-87-8P 149386-89-0P 149386-91-4P
 149386-92-5P 149386-93-6P 149386-95-8P
 149414-10-8P 149414-13-1P 149414-17-5P
 149414-19-7P 149414-21-1P 149414-23-3P
 149414-25-5P 149414-26-6P 149414-28-8P
 149414-30-2P 149414-33-5P 149414-35-7P
 149414-37-9P 149414-39-1P 149414-41-5P
 149414-42-6P 149414-43-7P 149414-45-9P
 149414-47-1P 149414-49-3P 149414-53-9P
 149414-61-9P 149414-64-2P 149414-65-3P

149437-56-9P 149437-57-0P 149437-58-1P



149437-60-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of, as antibacterial agent)


RN 149385-94-4 CAPLUS

CN Heptofuranuronic acid, 6-[(3-aminopropyl)methylamino]-1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)]- (9CI) (CA INDEX NAME)




RN 149385-96-6 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)]-6-[[3-[[[(1,1-dimethylethoxy)carbonyl]amino]propyl]methylamino]]- (9CI) (CA INDEX NAME)



RN 149386-00-5 CAPLUS


CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)]-6-[[3-[[8-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxooctyl]amino]propyl]methylamino]]- (9CI) (CA INDEX NAME)



RN 149386-06-1 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[methyl[3-[[[(phenylmethoxy)carbonyl]amino]acetyl]amino]propyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OBu-t


RN 149386-07-2 CAPLUS

CN Heptofuranuronic acid, 6-[[3-[(aminoacetyl)amino]propyl]methylamino]-1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 149386-14-1 CAPLUS


CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[[3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-methyl-1-oxopentyl]amino]propyl]methylamino]-, (S)- (9CI) (CA INDEX NAME)




RN 149386-25-4 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[[3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-6-[[[(phenylmethoxy)carbonyl]amino]hexyl]amino]propyl]methylamino]-, (S)- (9CI) (CA INDEX NAME)


PAGE 1-A






RN 149386-28-7 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[[3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-(phenylmethoxy)butyl]amino]propyl]methylamino]-, [R-(R*,S*)]]- (9CI) (CA INDEX NAME)




RN 149386-29-8 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[[3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-hydroxy-1-oxobutyl]amino]propyl]methylamino]-, [R-(R*,S*)]]- (9CI) (CA INDEX NAME)



RN 149386-37-8 CAPLUS
 CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[[3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,4-dioxo-4-(phenylmethoxy)butyl]amino]propyl]methylamino]-, (S)- (9CI)
 (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


—OBu-t

RN 149386-38-9 CAPLUS
 CN Heptofuranuronic acid, 6-[[3-[[3-carboxy-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]propyl]methylamino]-1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-, (S)- (9CI)
 (CA INDEX NAME)




RN 149386-40-3 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[[3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-phenylpropyl]amino]propyl]methylamino]-, (S)- (9CI) (CA INDEX NAME)




RN 149386-46-9 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[[3-[[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl]-L-alanyl]amino]propyl]methylamino]- (9CI) (CA INDEX NAME)




RN 149386-50-5 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[[3-(formylamino)propyl]methylamino]- (9CI) (CA INDEX NAME)




RN 149386-57-2 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy) carbonyl] amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[methyl 3-[(3-pyridinylcarbonyl) amino]propyl]amino]- (9CI) (CA INDEX NAME)




RN 149386-60-7 CAPLUS

CN Heptofuranuronic acid, 6-[[3-[(4-cyano-2,3,5,6-tetrafluorophenyl) amino]propyl]methylamino]-1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy) carbonyl] amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 149386-66-3 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[methyl 3-[(1-oxotetradecyl)amino]propyl]amino]-(9CI) (CA INDEX NAME)




RN 149386-69-6 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[methyl 3-[(4-pentylcyclohexyl)carbonyl]amino]propyl]amino]-, trans- (9CI) (CA INDEX NAME)




RN 149386-72-1 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[methyl 3-[(1-oxo-10-undecenyl)amino]propyl]amino]- (9CI) (CA INDEX NAME)




RN 149386-76-5 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[methyl 3-[[[4-(octyloxy)phenyl]acetyl]amino]propyl]amino]- (9CI) (CA INDEX NAME)




RN 149386-79-8 CAPLUS

CN Heptofuranuronic acid, 6-[[3-[[[4-butoxyphenyl]acetyl]amino]propyl]methylamino]-1,6-dideoxy-5-O-[5-deoxy-5-[[[1,1-dimethylethoxy]carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-(9CI)
(CA INDEX NAME)




RN 149386-81-2 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[1,1-dimethylethoxy]carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[methyl[3-[[4-(octyloxy)benzoyl]amino]propyl]amino]-(9CI) (CA INDEX NAME)




RN 149386-83-4 CAPLUS


CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy) carbonyl] amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[methyl 3-[[[2-(octyloxy) phenyl] acetyl] amino]propyl] amino]- (9CI) (CA INDEX NAME)



RN 149386-85-6 CAPLUS


CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy) carbonyl] amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[methyl 3-[[[3-(octyloxy) phenyl] acetyl] amino]propyl] amino]- (9CI) (CA INDEX NAME)

COCCCN(C)CCCC(=O)C=Cc1ccc(cc1)OCCCCCCCC




RN 149386-89-0 CAPLUS

CN Heptofuranuronic acid, 6-[[3-[(aminoiminomethyl)amino]propyl]methylamino]-1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)]- (9CI) (CA INDEX NAME)





RN 149386-91-4 CAPLUS

CN Heptofuranuronic acid, 5-O-[5-[(aminoiminomethyl)amino]-5-deoxy-β-D-ribofuranosyl]-1,6-dideoxy-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[[3-[[[(1,1-dimethylethoxy)carbonyl]amino]propyl]methylamino]- (9CI) (CA INDEX NAME)




RN 149386-92-5 CAPLUS

CN Heptofuranuronic acid, 5-O-[5-[(aminoiminomethyl)amino]-5-deoxy-β-D-ribofuranosyl]-6-[(3-aminopropyl)methylamino]-1,6-dideoxy-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 149386-93-6 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[[3-[[[(1,1-dimethylethoxy)carbonyl]amino]propyl]methylamino]-, methyl ester (9CI) (CA INDEX NAME)



RN 149386-95-8 CAPLUS


CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[[3-[[[(1,1-dimethylethoxy)carbonyl]amino]propyl]methylamino]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 149414-10-8 CAPLUS


CN Heptofuranuronic acid, 6-[[3-[[6-amino-2-[[[(1,1-

dimethylethoxy) carbonyl] amino] -1-oxohexyl] amino] propyl] methylamino] -1,6-dideoxy-5-O- [5-deoxy-5- [[(1,1-dimethylethoxy) carbonyl] amino] -β-D-ribofuranosyl] -1- (3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl) - (9CI) (CA INDEX NAME)



RN 149414-13-1 CAPLUS


CN Heptofuranuronic acid, 1,6-dideoxy-5-O- [5-deoxy-5- [[(1,1-dimethylethoxy) carbonyl] amino] -β-D-ribofuranosyl] -1- (3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl) -6- [[3- [[(1,1-dimethylethoxy) carbonyl] amino] propyl] dimethylammonio] -, iodide, phenylmethyl ester (9CI) (CA INDEX NAME)



● I⁻


RN 149414-17-5 CAPLUS


CN Heptofuranuronic acid, 1,6-dideoxy-5-O- [5-deoxy-5- [[(1,1-dimethylethoxy) carbonyl] amino] -β-D-ribofuranosyl] -1- (3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl) -6- [methyl [3- [[(4-phenoxyphenyl) acetyl] amino] propyl] amino] - (9CI) (CA INDEX NAME)





RN 149414-19-7 CAPLUS
 CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[[3-[[[4-(1-ethylbutoxy)phenyl]acetyl]amino]propyl]methylamino]- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 149414-21-1 CAPLUS
 CN Heptofuranuronic acid, 6-[[3-[[[4-(cycloheptyloxy)phenyl]acetyl]amino]propyl]methylamino]-1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-(9CI) (CA INDEX NAME)



RN 149414-23-3 CAPLUS
 CN Heptofuranuronic acid, 6-[[3-[[[4-[(6-cyanoheptyl)oxy]phenyl]acetyl]amino]p


ropyl]methylamino]-1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)]- (9CI) (CA INDEX NAME)




RN 149414-25-5 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)]-6-[methyl[3-[[[4-[[[(phenylmethoxy)carbonyl]amino]phenyl]acetyl]amino]propyl]amino]]- (9CI) (CA INDEX NAME)


PAGE 1-A







RN 149414-26-6 CAPLUS

CN Heptofuranuronic acid, 6-[[3-[[[(4-aminophenyl)acetyl]amino]propyl]methylamino]-1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-(9CI)
(CA INDEX NAME)





RN 149414-28-8 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[methyl 3-[[[4-[(1-oxoheptyl)amino]phenyl]acetyl]amino]propyl]amino]-(9CI) (CA INDEX NAME)




RN 149414-30-2 CAPLUS
 CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[methyl[3-[[[4-[(1-oxoundecyl)amino]phenyl]acetyl]amino]propyl]amino] - (9CI) (CA INDEX NAME)




RN 149414-33-5 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy) carbonyl] amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[methyl[3-[[[(1-octyl-1H-imidazol-4-yl)acetyl] amino]propyl]amino]- (9CI) (CA INDEX NAME)




RN 149414-35-7 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[methyl[3-[[[4-(octyloxy)phenyl]methyl]amino]propyl]amino]- (9CI) (CA INDEX NAME)




RN 149414-37-9 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[methyl[3-[(phenylmethyl)amino]propyl]amino]- (9CI) (CA INDEX NAME)




RN 149414-39-1 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[methyl[3-[[[4-(octyloxy)phenyl]sulfonyl]amino]propyl]amino]- (9CI) (CA INDEX NAME)




RN 149414-41-5 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[4-(octyloxy)phenyl]sulfonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[[3-[[[(1,1-dimethylethoxy)carbonyl]amino]propyl]methylamino]- (9CI) (CA INDEX NAME)




RN 149414-42-6 CAPLUS

CN Heptofuranuronic acid, 6-[(3-aminopropyl)methylamino]-1,6-dideoxy-5-O-[5-deoxy-5-[[[4-(octyloxy)phenyl]sulfonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 149414-43-7 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy) carbonyl] amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[[3-[[[[[(1,1-dimethylethoxy) carbonyl] amino] [4-(octyloxy) phenyl] acetyl] amino] propyl] methylamino]-, (R)- (9CI) (CA INDEX NAME)




RN 149414-45-9 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy) carbonyl] amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[[3-[[[[2-(1,1-dimethylethoxy)-2-oxoethoxy] imino] [4-(octyloxy) phenyl] acetyl] amino] propyl] methylamino]- (9CI) (CA INDEX NAME)




RN 149414-47-1 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[1,1-dimethylethoxy) carbonyl] amino] -β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[methyl [3-[[[4-(octyloxy)phenyl] [(tetrahydro-2H-pyran-2-yl)oxy] imino] acetyl] amino] propyl] amino]- (9CI) (CA INDEX NAME)




RN 149414-49-3 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[1,1-dimethylethoxy) carbonyl] amino] -β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[methyl [3-[[[4-(octyloxy)phenyl] [(tetrahydro-2H-pyran-2-yl)oxy] acetyl] amino] propyl] amino]- (9CI) (CA INDEX NAME)




RN 149414-53-9 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[[3-(dimethylamino)propyl]methylanino]-(9CI)
(CA INDEX NAME)




RN 149414-61-9 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[methyl 3-[[[4-(octyloxy)phenyl]acetyl]amino]propyl]amino]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 149414-64-2 CAPLUS

CN Glycine, N-[1,6-dideoxy-5-O-[5-deoxy-5-[[1,1-dimethylethoxy]carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[[3-[[1,1-dimethylethoxy]carbonyl]amino]propyl]methylamino]heptofuranuronoyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 149414-65-3 CAPLUS



CN Glycine, N-[1,6-dideoxy-5-O-[5-deoxy-5-[[1,1-dimethylethoxy]carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[[3-[[1,1-dimethylethoxy]carbonyl]amino]propyl]methylamino]heptofuranuronoyl]- (9CI) (CA INDEX NAME)




RN 149437-56-9 CAPLUS
 CN Heptofuranuronic acid, 5-O-[5-[(aminoiminomethyl)amino]-5-deoxy-β-D-ribofuranosyl]-1,6-dideoxy-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[methyl[3-[[[4-(octyloxy)phenyl]acetyl]amino]propyl]amino]- (9CI) (CA INDEX NAME)



RN 149437-57-0 CAPLUS
 CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[[[3-[[[4-[[[8-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxooctyl]amino]phenyl]acetyl]amino]propyl]methylamino]- (9CI) (CA INDEX NAME)




RN 149437-58-1 CAPLUS
 CN Heptofuranuronic acid, 1,6-dideoxy-5-O- [5-deoxy-5- [[(1,1-dimethylethoxy) carbonyl] amino] -β-D-ribofuranosyl] -1- (3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl) -6- [methyl [3- [[4- (octylamino) phenyl] acetyl] amino] propyl] amino] - (9CI) (CA INDEX NAME)




RN 149437-60-5 CAPLUS

CN Heptofuranuronic acid, 1,6-dideoxy-5-O-[5-deoxy-5-[[1,1-dimethylethoxy)carbonyl]amino]-β-D-ribofuranosyl]-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-6-[[3-[[4-[[1-[(1,1-dimethylethoxy)carbonyl]heptyl]oxy]benzoyl]amino]propyl]methylamino]- (9CI) (CA INDEX NAME)


PAGE 1-A






L18 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Studies on immunoadjuvant active compounds. Part VI. Syntheses and immunoadjuvant activity of some carbohydrate analogs of N-acetylmuramyl-L-alanyl-D-isoglutamine
 IT 66166-90-3
 RL: RCT (Reactant); RACT (Reactant or reagent) (reduction of)
 RN 66166-90-3 CAPLUS
 CN β -D-Xylofuranoside, phenylmethyl 2-deoxy-2-[[[(phenylmethoxy)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 TI The behavior of some aldoses with 2,2-dialkoxypropane-N,N-dimethylformamide-p-toluenesulfonic acid. Part IX. Synthesis of 2,5-diacetamido-2,5-dideoxy- and 2,3,5-triacetamido-2,3,5-trideoxy-D-aldopentofuranose derivatives
 IT 66166-90-3
 RL: RCT (Reactant); RACT (Reactant or reagent) (catalytic hydrogenation of)
 RN 66166-90-3 CAPLUS
 CN β -D-Xylofuranoside, phenylmethyl 2-deoxy-2-[[[(phenylmethoxy)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RL: RCT (Reactant); RACT (Reactant or reagent)
(mesylation of)

L18 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

TI Studies on hetero sugars. Part IV. Synthesis of a 2-acetamido-5-amino-2,5-dideoxy-D-xylopyranosyl derivative


IT 66166-90-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and tosylation of)

RN 66166-90-3 CAPLUS

CN β -D-Xylofuranoside, phenylmethyl 2-deoxy-2-
[[(phenylmethoxy) carbonyl] amino] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

TI Studies on heterosugars. Part II. Synthesis of 2,4-diamino-2,4-dideoxy-L-arabinose derivatives (prumycin derivatives)


IT 66166-91-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and benzylation of)

RN 66166-91-4 CAPLUS

CN β -D-Xylofuranoside, phenylmethyl 2-deoxy-2-
[[(phenylmethoxy) carbonyl] amino] -5-O- (triphenylmethyl) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 61236-74-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolytic debenzoylation of)

RN 61236-74-6 CAPLUS

CN β -D-Xylofuranoside, phenylmethyl 2-deoxy-2-
[[(phenylmethoxy) carbonyl] amino] -, 3-benzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 66166-90-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and tritylation of)

RN 66166-90-3 CAPLUS

CN β -D-Xylofuranoside, phenylmethyl 2-deoxy-2-
[[(phenylmethoxy) carbonyl] amino] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

TI Synthesis of prumycin and related compounds


IT 61236-74-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)

RN 61236-74-6 CAPLUS

CN β -D-Xylofuranoside, phenylmethyl 2-deoxy-2-
[[(phenylmethoxy) carbonyl] amino] -, 3-benzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L18 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

TI A new synthesis of Prumycin


IT 61236-74-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and hydrolytic debenzoylation of)
 RN 61236-74-6 CAPLUS
 CN β -D-Xylofuranoside, phenylmethyl 2-deoxy-2-
 [[(phenylmethoxy)carbonyl]amino]-, 3-benzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L18 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Preparation of aminomercapto furanose sugars from dithiocarbamoyl
 derivatives
 IT 37063-17-5P 37075-01-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 37063-17-5 CAPLUS
 CN α -D-Arabinofuranoside, methyl 3-deoxy-3-
 [[(methylthio)thioxomethyl]amino]-, 5-(methyl carbonate) (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




RN 37075-01-7 CAPLUS
 CN α -D-Arabinofuranoside, methyl 3-deoxy-3-
 [[(methylthio)thioxomethyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L18 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Synthetic nucleosides. LXVIII. Studies on the synthesis of cis-2,3-diamino sugars. 8. Derivatives of 2,3-diamino-2,3-dideoxy-D-ribose and 2,3-dideoxy-2,3-imino-D-ribose
 IT 5974-97-0P, Arabinofuranoside, methyl 3-deoxy-3-ureido-, β -D-
 RL: PREP (Preparation)
 (preparation of)
 RN 5974-97-0 CAPLUS
 CN Arabinofuranoside, methyl 3-deoxy-3-ureido-, β -D- (8CI) (CA INDEX NAME)

Absolute stereochemistry.




L18 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Use of a complex neighboring group to prepare amino(mercapto)furanose sugars
 IT 37063-17-5P, Arabinofuranoside, methyl 3-deoxy-3-
 [(dithiocarboxy)amino]-, methyl ester, 5-(Me carbonate), α -D-
 37075-01-7P, Arabinofuranoside, methyl 3-deoxy-3-
 [(dithiocarboxy)amino]-, methyl ester, α -D-
 RL: PREP (Preparation)
 (preparation of)
 RN 37063-17-5 CAPLUS
 CN α -D-Arabinofuranoside, methyl 3-deoxy-3-
 [[(methylthio)thioxomethyl]amino]-, 5-(methyl carbonate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 37075-01-7 CAPLUS
 CN α -D-Arabinofuranoside, methyl 3-deoxy-3-
 [[(methylthio)thioxomethyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



(FILE 'HOME' ENTERED AT 08:54:03 ON 27 MAR 2007)

FILE 'REGISTRY' ENTERED AT 08:54:15 ON 27 MAR 2007

L1 STRUCTURE UPLOADED
L2 50 S L1
L3 STRUCTURE UPLOADED
L4 7 S L3 SUB=L2 SAM
L5 STRUCTURE UPLOADED
L6 4 S L5 SUB=L2 SAM
L7 STRUCTURE UPLOADED
L8 STRUCTURE UPLOADED
L9 STRUCTURE UPLOADED
L10 27 S (L7 OR L8 OR L9) SUB=L2 SAM
L11 STRUCTURE UPLOADED
L12 STRUCTURE UPLOADED
L13 STRUCTURE UPLOADED
L14 1 S (L11 OR L12 OR L13) SUB=L2 SAM
L15 3350 S L1 SSS FULL
L16 124 S (L11 OR L12 OR L13) SUB=L15 FULL
L17 109 S (L7 OR L8 OR L9) SUB=L16 FULL

FILE 'CAPLUS' ENTERED AT 09:13:39 ON 27 MAR 2007

L18 16 S L17

FILE 'REGISTRY' ENTERED AT 09:14:31 ON 27 MAR 2007